Chronic Inflammatory Dermatoses: Designing Trials for Late-Stage Success

Chronic, relapsing inflammatory dermatoses such as psoriasis, atopic dermatitis, vitiligo and hidradenitis suppurativa pose distinct development challenges that traditional clinical trial models were not designed to address. While therapeutic innovation has accelerated, many promising programs struggle in late-stage development, not due to a lack of efficacy, but because trial designs do not fully capture durability, long-term safety and improvements in patient experience.

In this webinar, the featured speaker will outline a strategic framework for designing Phase II and Phase III trials positioned for regulatory, clinical and commercial success in chronic dermatoses. The speaker will discuss how to move beyond short-term response rates to sustained disease control, integrate clinician and patient perspectives into endpoint strategy, design for what happens after the primary endpoint and manage execution risks such as variability in investigator scoring and participant burden.

For sponsors advancing dermatology assets, these strategic decisions shape not only approval and labeling outcomes, but also competitive differentiation and long-term market viability.

Register for this webinar to learn how the inflammatory dermatoses trial design can support late-stage success.

Speaker

Ayman Farahat, MD, Vice President, Medical Affairs, Global Head of Dermatology, Premier Research

Dr. Ayman Farahat is a board-certified Dermatologist and seasoned clinical development leader with over 20 years of experience guiding global dermatology programs from early-phase strategy through regulatory submission. As Global Head of Dermatology at Premier Research, he partners with biotech innovators to design and execute efficient, fit-for-purpose clinical trials that accelerate development and de-risk decision-making.

With over a decade of clinical dermatology practice and two decades in drug development, Dr. Farahat brings deep therapeutic insight across a broad range of dermatologic indications, including chronic inflammatory dermatoses, aesthetic conditions and procedural dermatology. He has supported MedTech sponsors in the successful design and execution of clinical studies for dermatologic devices and technologies. His strategic leadership helps emerging biotechnology companies navigate complex regulatory landscapes and bring transformative dermatologic therapies to market.

Message Presenter